phrykt

Volitionrx Ltd (VNRX): who owns it and who trades it

As of Nov 16, 2026, VNRX insiders reported 1 purchase worth $7K in the last 12 months. The largest buyer was Cameron John Reynolds (CEO), with $7K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Volitionrx

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, VNRX insiders reported $7K of open-market purchases and $0 of sales.

Purchases, 12 months
$7K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 17, 2025
Filed Nov 17, 2025

Purchases and sales by month

$1$1DecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 17, 2025Cameron John ReynoldsCEOPurchase20,000$0.35$7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Cameron John ReynoldsPresident and CEO, Director$7K–Nov 17, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VNRX short interest

High short interest. 10.2% of VNRX shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 232%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.40M VNRX shares were sold short, 10.2% of the shares outstanding, up 21.9% from the report before. At the average daily volume of 1.18M shares, buying them all back would take about 1.2 trading days (days to cover).

Shares short, % of all shares

10.2%May 15Oct 3018.7%

Days to cover

1.2May 15Oct 301.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.40M10.23%+22%1.18M1.2
Oct 15, 20261.15M8.39%-4%1.74M1.0
Sep 30, 20261.20M8.77%+19%4.43M1.0
Sep 15, 20261.00M7.36%-55%1.73M1.0
Aug 31, 20262.22M16.29%+225%40.22M1.0
Aug 14, 2026683,8925.01%+27%1.62M1.0
Jul 31, 2026538,5290.34%+101%308,4391.8
Jul 15, 2026267,6870.17%-17%212,1231.3
Jun 30, 2026322,4180.20%+27%296,8361.1
Jun 15, 2026254,1250.16%-35%424,4981.0
May 29, 2026389,0050.25%-7%293,2281.3
May 15, 2026420,0840.27%+56%308,3611.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Volitionrx company events

Volitionrx filed 24 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Oct 27, 2026.

  1. Oct 27, 2026AgreementAs previously reported, VolitionRx Limited and Lind Global Asset Management XII LLC entered into a Securities Purchase Agreement, dated May 15, 2025, as amended and restated on January 7, 2026, pursuant to which the Company issued and sold to Lind in addition to certain common stock purchase… Filing
  2. Sep 25, 2026SharesSold new shares outside a public offering. Filing
  3. Sep 15, 2026SharesSold new shares outside a public offering. Filing
  4. Sep 14, 2026AnnouncementNote Prepayment As previously reported, VolitionRx Limited and Lind Global Asset Management XII LLC entered into a Securities Purchase Agreement, dated May 15, 2025, as amended and restated on January 7, 2026, pursuant to which the Company issued and sold to Lind (i) that certain senior secured… Filing
  5. Sep 2, 2026AgreementAs previously reported, VolitionRx Limited and Lind Global Asset Management XII LLC entered into a Securities Purchase Agreement, dated May 15, 2025, as amended and restated on January 7, 2026, pursuant to which the Company issued and sold to Lind (i) that certain senior secured convertible… Filing
  6. Sep 2, 2026SharesSold new shares outside a public offering. Filing
  7. Aug 24, 2026SharesSold new shares outside a public offering. Filing
  8. Aug 13, 2026ResultsReleased financial results. Filing
  9. Aug 7, 2026SharesSold new shares outside a public offering. Filing
  10. Jul 21, 2026VoteReported shareholder vote results. Filing
  11. Jun 18, 2026SharesSold new shares outside a public offering. Filing
  12. Jun 10, 2026AgreementVolitionRx Limited entered into a securities purchase agreement with the purchasers listed on the signature pages thereto, in connection with the Company’s offer of an aggregate of 2,960,000 shares of its common stock, par value $0.001 per share, together with accompanying common stock purchase… Filing
  13. May 22, 2026AgreementAs previously reported, VolitionRx Limited issued to Lind Global Asset Management XII LLC (i) that certain senior secured convertible promissory note in the original principal amount of $7.5 million on May 15, 2025, pursuant to that certain securities purchase agreement, dated May 15, 2025, by and… Filing
  14. May 15, 2026LeadershipMickie Henshall notified the Board of Directors of VolitionRx Limited of her decision not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders. Filing
  15. May 14, 2026ResultsReleased financial results. Filing
  16. Apr 28, 2026SharesChanged the rights of its shareholders. Filing
  17. Apr 23, 2026ListingAs previously disclosed under Item 3.01 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 9, 2026, VolitionRx Limited received a notice from the NYSE American LLC indicating that the Company was not in compliance with the NYSE American continued listing… Filing
  18. Apr 17, 2026AnnouncementAs previously disclosed under Item 5.07 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2026, at a special meeting held on March 31, 2026, the shareholders of VolitionRx Limited approved a proposal granting the Company’s board of directors the… Filing
  19. Apr 1, 2026VoteReported shareholder vote results. Filing
  20. Mar 31, 2026ResultsReleased financial results. Filing
  21. Feb 20, 2026SharesSold new shares outside a public offering. Filing
  22. Feb 9, 2026ListingVolitionRx Limited received a notice from the NYSE American LLC stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide requiring a company to have stockholders’ equity of at least $2.0… Filing
  23. Jan 8, 2026AgreementVolitionRx Limited entered into an amended and restated securities purchase agreement with Lind Global Asset Management XII LLC, a Delaware limited liability company. Filing
  24. Dec 11, 2025LeadershipVolition Veterinary Diagnostics Development, LLC, a majority-owned subsidiary of VolitionRx Limited, provided notice of termination of its employment agreement with Dr. Salvatore Thomas Butera, the Chief Executive Officer of Volition Veterinary, effective as of January 31, 2026. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Volitionrx financials

Famous investors that hold VNRX

1 of the 50 well-known investors we track reported holding VNRX in their latest 13F filing. The largest position is Ken Griffin's, worth $12.3K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202647,656$12.3K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Volitionrx Ltd (VNRX) stock

Are VNRX insiders buying or selling?

In the last 12 months, VNRX insiders reported 1 open-market purchase worth $7K and no sales. The latest trade was on Nov 17, 2025. See every trade.

What is the short interest in VNRX?

As of Oct 30, 2026, 1.40M VNRX shares were sold short, 10.2% of the shares outstanding, up 21.9% from the report before. At the average daily volume of 1.18M shares, buying them all back would take about 1.2 trading days (days to cover). See the history.

Which famous investors hold VNRX?

1 of the 50 well-known investors we track reported VNRX in their latest 13F filing, including Ken Griffin. The largest position is worth $12.3K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.